DARMSTADT, Germany, March 20, 2018 /CNW/ -- Merck KGaA, Darmstadt, Germany (XETRA: MRK, OTC Pink: MKKGY), a leading science and technology company, today announced that it will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on 22nd March 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
Recent Company Highlights
- Merck Achieves Targets for 2017 – Dividend to Increase
- Merck Announced Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
- Mavenclad (Cladribine Tablets) Receives First Approval in Latin America, following approval in the EU, Canada, Australia and Israel
- Merck Receives Patents for CRISPR Technology in U.S., Brazil, China, India, Japan, South Korea and Israel
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
SOURCE Merck KGaA
For further information: Merck KGaA, Investor Relations, [email protected], +49 6151 72 3321